Abstract Number: 2050 • ACR Convergence 2025
Efficacy and Safety of Antifibrotic Therapy in Autoimmune–Associated Interstitial Lung Disease: A Meta-Analysis
Background/Purpose: Autoimmune–associated interstitial lung disease (A‑ILD) which includes Rheumatoid arthritis associated interstitial lung disease (RA-ILD), Systemic Sclerosis associated interstitial lung disease (SS-ILD), and others is…Abstract Number: 1869 • ACR Convergence 2025
A miRNA signature consisting of high Let7i-5p, high miR-483-5p, low miR-223- 3p characterizes connective tissue diseases with interstitial lung disease
Background/Purpose: Patients with interstitial lung disease associated to a connective tissue disease (CTD-ILD) are a heterogeneous population both concerning mechanisms and trajectories. In an RNA…Abstract Number: 1728 • ACR Convergence 2025
Longitudinal Proteomic Signatures for Prediction of Immune-Related Adverse Events during Immune Checkpoint Inhibitors therapy: A Machine Learning-Guided Prospective Biomarker Discovery Study
Background/Purpose: Immune checkpoint inhibitors (ICIs), while revolutionary in cancer treatment, may induce severe or even fatal immune-related adverse event (irAE). The mechanisms underlying irAE development…Abstract Number: 1547 • ACR Convergence 2025
Anifrolumab In Systemic Lupus Erythematosus With Renal Involvement: National Multicenter Registry In Clinical Practice
Background/Purpose: Lupus Nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), occurring in up to 50% of patients. Currently, Anifrolumab (ANI) is approved…Abstract Number: 1431 • ACR Convergence 2025
Radiographic Sacroiliitis in Psoriatic Arthritis: Clinical, Laboratory, and Spinal Radiographic Correlates in an Indian Cohort
Background/Purpose: Axial involvement in psoriatic arthritis (PsA) is variable and influences treatment choices. Data on axial PsA in Indian patients, especially its clinical and radiographic…Abstract Number: 1269 • ACR Convergence 2025
Dress for success: Influence of Rheumatologist Demographics and Attire on Patients with Chronic Inflammatory Arthritis Perceptions
Background/Purpose: Physician sociodemographic factors and attire has been shown to influence patients’ trust. This study aimed to determine differences on patient perceptions of rheumatologist professionalism,…Abstract Number: 1122 • ACR Convergence 2025
A Retrospective Study of Adverse Cardiovascular Events in Patients Started on JAK Inhibitors at Two Major Health Systems in Northeast Ohio: Analysis of the 2019 JAK Inhibitors FDA Boxed Warning for Increased Risk of Serious Heart-Related Problems
Background/Purpose: Janus kinase (JAK) inhibitors are immunosuppressive medications that target the JAK-STAT signaling pathway. Tofacitinib (Xeljanz) was the first JAK inhibitor approved for the treatment…Abstract Number: 0990 • ACR Convergence 2025
An Fc-engineered Agonistic Anti-PD-1 Antibody Selectively Depletes PD-1+ cells and Attenuates T cell activation in vitro and in vivo in a Xenogeneic Graft-versus-Host Disease (GvHD) model
Background/Purpose: PD-1+ T cells play a pivotal role in the pathogenesis of autoimmune diseases, including rheumatoid arthritis. Therapeutic antibodies targeting PD-1 with both depleting and…Abstract Number: 0929 • ACR Convergence 2025
SP2H, a Targeted Degrader of STimulator of INterferon Genes (STING), selectively inhibits STING-driven inflammation in vitro and in vivo and improves survival in Trex1-/- mice
Background/Purpose: STING plays a critical role at the intersection of innate and adaptive immunity and has been linked to the pathogenesis of SSc and SLE.…Abstract Number: 0705 • ACR Convergence 2025
Multimodal Imaging Evaluation of Patients with Raynaud’s Phenomenon meeting the Criteria for “Early” Systemic Sclerosis according to LeRoy versus Healthy Controls: a Prospective Cross-sectional study
Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune disorder. To date, no comparative multi-modal imaging data exist for precursor patients, those with Raynaud’s phenomenon (RP)…Abstract Number: 0864 • ACR Convergence 2025
Immunophenotyping Reveals Upregulated IL-9R on Circulating T and B Cells in Dermatomyositis
Background/Purpose: Idiopathic inflammatory myopathies (IIM), or myositis, comprise a group of autoimmune diseases with significant morbidity, yet the pathogenesis of myositis remains incompletely understood. In…Abstract Number: 0484 • ACR Convergence 2025
Comparable Efficacy of FK-Tocilizumab and Reference Tocilizumab in Rheumatoid Arthritis Patients With and Without Prior Biologic Exposure
Background/Purpose: Biosimilars offer comparable efficacy and safety to their originators, thereby improving patient access to affordable treatments. FK-Tocilizumab (FK-toci) is the first tocilizumab biosimilar approved…Abstract Number: 0278 • ACR Convergence 2025
Classic and Clinically Amyopathic Dermatomyositis: Autoantibody Positivity
Background/Purpose: Dermatomyositis (DM) is an idiopathic inflammatory myopathy subclassified as classic (CDM) and clinically amyopathic (CADM). It can involve myositis-associated (MAA) and myositis-specific (MSA) autoantibodies.…Abstract Number: 0239 • ACR Convergence 2025
Safety of Rilzabrutinib, a BTK Inhibitor, in Adult Patients with IgG4-related disease (IgG4-RD) in a 52-week Phase 2 Open-label Study
Background/Purpose: IgG4- related disease (IgG4-RD) is a chronic, progressive, immune-mediated fibrotic disease with limited treatment options. Rilzabrutinib is an orally available, reversible, inhibitor of Bruton's…Abstract Number: 0138 • ACR Convergence 2025
Evaluating Artificial Intelligence for Diagnosing Antiphospholipid Syndrome in Pulmonary Embolism Case Reports: A Prompt-Based Analysis
Background/Purpose: Antiphospholipid syndrome (APS) is a complex autoimmune prothrombotic disorder that can present with venous or arterial thromboses, often masquerading as unprovoked pulmonary embolism (PE).…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 101
- Next Page »